D059767PhysiologyG02.111.222.700G05.219.700G05.728.615.612790.988576Recombinational DNA Repairplugins:TwitterTwitterprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAlexanderPearson1nJsCrMGFuKMsW9naE/t8mL1sc65/A==Alexander Pearson41.7886000000000087.598699999999993513Pearson, AlexanderAssociate ProfessorRadiation and Cellular OncologyMedicine-Hematology and OncologyPediatrics-Hematology and Oncology32064511DiNapoli SE, Martinez-McFaline R, Gribbin CK, Wrighton PJ, Balgobin CA, Nelson I, Leonard A, Maskin CR, Shwartz A, Quenzer ED, Mailhiot D, Kao C, McConnell SC, de Jong JLO, Goessling W, Houvras YNucleic acids researchSynthetic CRISPR/Cas9 reagents facilitate genome editing and homology directed repair. Nucleic Acids Res. 2020 04 17; 48(7):e38.Nucleic Acids Res2020-04-17T00:00:002020Synthetic CRISPR/Cas9 reagents facilitate genome editing and homology directed repair.EricPolleyEric Polley41.7886000000000087.598699999999994014Polley, EricAssociate Professor33028596Yadav S, Kasi PM, Bamlet WR, Ho TP, Polley EC, Hu C, Hart SN, Rabe KG, Boddicker NJ, Gnanaolivu RD, Lee KY, Lindstrom TH, Petersen GM, Couch FJ, McWilliams RRClinical cancer research : an official journal of the American Association for Cancer ResearchEffect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. Clin Cancer Res. 2020 12 15; 26(24):6505-6512.Clin Cancer Res2020-10-07T00:00:002020Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.33609447Richardson ME, Hu C, Lee KY, LaDuca H, Fulk K, Durda KM, Deckman AM, Goldgar DE, Monteiro ANA, Gnanaolivu R, Hart SN, Polley EC, Chao E, Pesaran T, Couch FJAmerican journal of human geneticsStrong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. Am J Hum Genet. 2021 03 04; 108(3):458-468.Am J Hum Genet2021-02-19T00:00:002021Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.Public Health Scienceshttps://health.uchicago.edu/research/biostatistics-laboratoryBiostatistics Laboratoryhttps://scholar.google.com/citations?user=v4vmLQUAAAAJGoogle Scholarhttp://bishoplab.bsd.uchicago.edu/Bishop Lab Website@Lab_Pearson32471999Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NCNature communicationsHomologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun. 2020 05 29; 11(1):2662.Nat Commun2020-05-29T00:00:002020Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.34906376Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RLGynecologic oncologyImpact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.Gynecol Oncol2021-12-11T00:00:002021Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.1.089780.03820567research area of0.8529710.1545889subject area forUniversity of ChicagoGiniFleming0GRlDqwcF+v5hHlsaUXv9Gq0+s+oGini Fleming41.78927490000000-87.601250000000001804Fleming, GiniProfessorDouglas K.Bishop02BgGKkaCczbgn4qdUXm+mb7+MTz7LFLDouglas K. Bishop41.78927490000000-87.601250000000002358Bishop, Douglas K.ProfessorJillDe Jong3WZsAa4bHszMknJtY0fp/Cv/+94=Jill De Jong41.78927490000000-87.60125000000000324De Jong, JillAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessor